UroGen Pharma heads into its May 11 earnings report with short sellers pulling back even as the stock's structural bear case remains firmly intact.
The most striking feature of the past month is the divergence between price and positioning. The stock has climbed 27% over the past month to $23.83, yet short interest has moved in the opposite direction — falling roughly 7% over the same period to 16.8% of the free float. That is still a meaningfully elevated level for a small-cap biotech, but the direction of travel matters: bears have been covering, not adding, into a rising tape.
The lending market tells a similarly relaxed story. Borrow availability is loose, with cost to borrow running at just 0.58% annually — barely changed over the past month — and availability well above the danger zone. The ORTEX short score, while still elevated at 75.5 out of 100, has eased from a recent peak of 79.0 on April 27, tracking the unwinding of short positions. What is notable, though, is that availability reached 100% utilisation at some point in the past 52 weeks — a reminder that the lending market here has been considerably tighter before, and short interest at 16.8% of float means the structure for a squeeze still exists if sentiment flips hard. Options positioning is calmer than hedging activity suggests. The put/call ratio has dropped to 0.56, running below its 20-day average of 0.62 and nearly 0.8 standard deviations beneath recent norms. Calls are leading puts heading into the print, a mild but real tilt toward upside positioning.
The Street remains constructive but selectively so. The consensus price target of roughly $34 implies around 43% upside from current levels — a gap wide enough to keep bulls engaged but narrow enough to suggest the recent 27% rally has consumed a meaningful chunk of the re-rating potential. The bull case rests on Jelmyto and Zusduri adoption trends, expanding payer coverage, and a permanent CMS J Code for Zusduri that should reduce reimbursement friction. Bears point to slower-than-expected commercial uptake, a still-negative P/E (currently –75.9x), and cash reserves of roughly $127 million that may need replenishment before the pipeline matures. The forward EPS improvement score ranks in the 99th percentile — the company's loss trajectory is narrowing fast — while EV/EBITDA has moved from deeply negative to an admittedly eye-watering 403x as revenue builds from a low base. Factor scores flag the short score rank at just the 6th percentile, underlining how structurally shorted this name remains relative to its peers.
On the institutional side, the register reflects concentrated specialist ownership. RTW Investments and Paradigm Biocapital together hold nearly 18.5% of shares, and several healthcare-focused funds — including Acorn Bioventures, MPM BioImpact, and OrbiMed — have been adding recently. American Century and Healthcare of Ontario each initiated new positions as of the March quarter, adding incremental buy-side support. The presence of these names suggests the institutionally held float is tightly held by investors with long investment horizons, which structurally limits the shares available to short sellers at scale.
Earnings history offers a limited reference point. The most recent comparable print — March 13, 2026 — produced a flat first-day reaction followed by a 6% five-day decline, suggesting the market was disappointed by execution even when the headline numbers were not catastrophic. With the stock now 27% higher than it was a month ago, the bar for the May 11 report is considerably higher. The key variable to watch is not the revenue line itself, but whether Zusduri prescription trends and Jelmyto reimbursement data show the inflection that bulls have been pricing in — and whether a short interest still near 17% of float finds a reason to accelerate the cover trade or reverse it.
See the live data behind this article on ORTEX.
Open URGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
